1
|
Tan F, Lu B, Liu Z, Chen G, Liu Y, Cheng F, Zhou Y. Identification and quantification of TBBPA and its metabolites in adult zebrafish by high resolution liquid chromatography tandem mass spectrometry. Microchem J 2020. [DOI: 10.1016/j.microc.2019.104566] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
2
|
Rochat B. From targeted quantification to untargeted metabolomics: Why LC-high-resolution-MS will become a key instrument in clinical labs. Trends Analyt Chem 2016. [DOI: 10.1016/j.trac.2016.02.009] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
3
|
Glauser G, Grund B, Gassner AL, Menin L, Henry H, Bromirski M, Schütz F, McMullen J, Rochat B. Validation of the Mass-Extraction-Window for Quantitative Methods Using Liquid Chromatography High Resolution Mass Spectrometry. Anal Chem 2016; 88:3264-71. [DOI: 10.1021/acs.analchem.5b04689] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Gaétan Glauser
- Neuchâtel
Platform of Analytical Chemistry, Institut de Chimie, Université de Neuchâtel, Neuchâtel, Switzerland
| | - Baptiste Grund
- Quantitative
Mass Spectrometry Facility, University Hospital of Lausanne, CHUV, 1011 Lausanne, Switzerland
| | - Anne-Laure Gassner
- Institut
de Police Scientifique, University of Lausanne, Batochime, 1015 Lausanne, Switzerland
| | - Laure Menin
- EPFL, Institut
of Chemical Sciences and Engineering, Batochime, 1015 Lausanne, Switzerland
| | - Hugues Henry
- BioID,
Department of Laboratories, University Hospital of Lausanne, CHUV, 1011 Lausanne, Switzerland
| | | | - Frédéric Schütz
- Swiss Institute
of Bioinformatics, Génopode, University of Lausanne, 1015 Lausanne, Switzerland
| | - Justin McMullen
- Quantitative
Mass Spectrometry Facility, University Hospital of Lausanne, CHUV, 1011 Lausanne, Switzerland
| | - Bertrand Rochat
- Quantitative
Mass Spectrometry Facility, University Hospital of Lausanne, CHUV, 1011 Lausanne, Switzerland
| |
Collapse
|
4
|
Gao H, Deng S, Obach RS. Unbiased Scanning Method and Data Banking Approach Using Ultra-High Performance Liquid Chromatography Coupled with High-Resolution Mass Spectrometry for Quantitative Comparison of Metabolite Exposure in Plasma across Species Analyzed at Different Dates. Anal Chem 2015; 87:11771-6. [DOI: 10.1021/acs.analchem.5b03469] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Hongying Gao
- Pharmacokinetics, Dynamics and Metabolism and ‡Biostatistics, Pfizer Inc., Groton, Connecticut 06340, United States
| | - Shibing Deng
- Pharmacokinetics, Dynamics and Metabolism and ‡Biostatistics, Pfizer Inc., Groton, Connecticut 06340, United States
| | - R. Scott Obach
- Pharmacokinetics, Dynamics and Metabolism and ‡Biostatistics, Pfizer Inc., Groton, Connecticut 06340, United States
| |
Collapse
|
5
|
Analytical challenges for conducting rapid metabolism characterization for QIVIVE. Toxicology 2015; 332:20-9. [DOI: 10.1016/j.tox.2013.08.010] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2012] [Revised: 08/05/2013] [Accepted: 08/13/2013] [Indexed: 12/22/2022]
|
6
|
Quantitative determination of azacitidine triphosphate in peripheral blood mononuclear cells using liquid chromatography coupled with high-resolution mass spectrometry. J Pharm Biomed Anal 2013; 90:7-14. [PMID: 24317024 DOI: 10.1016/j.jpba.2013.11.010] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2013] [Revised: 11/07/2013] [Accepted: 11/09/2013] [Indexed: 11/22/2022]
Abstract
Azacitidine is a cytidine analog used in the treatment of myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia. The pharmacological effect of azacitidine arises after incorporation into the DNA and RNA. To this end, the drug first has to be converted into its triphosphate forms. This paper describes the development of an assay for quantitative determination of azacitidine triphosphate (aza-CTP) in peripheral blood mononuclear cells (PBMCs). To quantify aza-CTP, separation from the endogenous nucleotides cytidine triphosphate (CTP) and uridine triphosphate (UTP) is required. This was a challenge as the structures of these nucleotides are highly similar and the monoisotopic molecular masses of aza-CTP, UTP and the naturally occurring [(13)C]- and [(15)N]-isotopes of CTP differ less than 0.02 Da. Efforts to select a specific MS(2)-fragment for aza-CTP using a triple quadrupole mass spectrometer remained without success. Therefore, we investigated the feasibility to separate these highly resembling nucleotides based on accurate mass spectrometry using a linear trap quadrupole (LTQ) coupled with an Orbitrap. The LTQ-Orbitrap was able to differentiate between aza-CTP and the endogenous nucleotides UTP and [(13)C]-CTP. There was no baseline resolution between aza-CTP and [(15)N]-CTP, but the [(15)N]-CTP interference was low. For quantification, extracted ion chromatograms were obtained for the accurate m/z window of the aza-CTP product ion. The assay was able to determine aza-CTP concentrations in PBMC lysate from 40.7 to 281 nM. Assuming that an average cell suspension extracted from 16 mL blood contains 10 to 42 million PBMCs per mL, this range corresponds with 2.58/10.9-17.8/74.9 pmol aza-CTP per million PBMCs. Intra-assay accuracies were between -1.1 and 9.5% deviation and coefficient of variation values were ≤13.2%. The assay was successfully applied to quantify aza-CTP in samples from two patients treated with azacitidine. Aza-CTP concentrations up to 19.0 pmol per million PBMCs were measured. This is the first time that aza-CTP concentrations were quantified in PBMCs from patients treated with azacitidine.
Collapse
|
7
|
Determination of rosiglitazone and 5-hydroxy rosiglitazone in rat plasma using LC–HRMS by direct and indirect quantitative analysis: a new approach for metabolite quantification. Bioanalysis 2013; 5:1873-81. [DOI: 10.4155/bio.13.140] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Background: With recent advances in mass spectrometry instrumentation, HRMS is of increasing interest for quantitative bioanalysis due to its high sensitivity, rapid acquisition of full scan data, and advanced software for metabolite identification. In particular, there is strong interest in use of HRMS for simultaneous quantification of parent drug and metabolites without authentic metabolite standard materials. Materials & methods: Rosiglitazone and 5-hydroxy rosiglitazone in rat plasma were analyzed using LC–Q-TOF by both direct and indirect quantitative analysis. Direct quantitative analysis used an authentic metabolite standard (5-hydroxy rosiglitazone). Indirect quantitative analysis firstly used the parent drug (rosiglitazone) calibration curve to provide a semiquantitative measure of metabolite concentration. A correction factor was then applied to the original data to re-calculate the 5-hydroxy rosiglitazone metabolite concentration. Results: The ratio of the calibration curve slope of rosiglitazone to that of 5-hydroxy rosiglitazone was determined to be 2.09 ± 0.28 using different batches of mobile phases and columns. The correction factor 2.09 was then used to correct for the 5-hydroxy rosiglitazone concentrations found from the semiquantitative results using the rosiglitazone calibration standard curve. The concentrations of 5-hydroxy rosiglitazone found by direct and indirect quantitative analysis were highly comparable (within ±8%). Conclusion: Indirect quantitative analysis provides an alternative approach for metabolite quantification for discovery PK studies.
Collapse
|
8
|
Wei C, Chupak LS, Philip T, Johnson BM, Gentles R, Drexler DM. Screening and characterization of reactive compounds with in vitro peptide-trapping and liquid chromatography/high-resolution accurate mass spectrometry. ACTA ACUST UNITED AC 2013; 19:297-307. [PMID: 23796688 DOI: 10.1177/1087057113492852] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The present study describes a novel methodology for the detection of reactive compounds using in vitro peptide-trapping and liquid chromatography-high-resolution accurate mass spectrometry (LC-HRMS). Compounds that contain electrophilic groups can covalently bind to nucleophilic moieties in proteins and form adducts. Such adducts are thought to be associated with drug-mediated toxicity and therefore represent potential liabilities in drug discovery programs. In addition, reactive compounds identified in biological screening can be associated with data that can be misinterpreted if the reactive nature of the compound is not appreciated. In this work, to facilitate the triage of hits from high-throughput screening (HTS), a novel assay was developed to monitor the formation of covalent peptide adducts by compounds suspected to be chemically reactive. The assay consists of in vitro incubations of test compounds (under conditions of physiological pH) with synthetically prepared peptides presenting a variety of nucleophilic moieties such as cysteine, lysine, histidine, arginine, serine, and tyrosine. Reaction mixtures were analyzed using full-scan LC-HRMS, the data were interrogated using postacquisition data mining, and modified amino acids were identified by subsequent LC-HRMS/mass spectrometry. The study demonstrated that in vitro nucleophilic peptide trapping followed by LC-HRMS analysis is a useful approach for screening of intrinsically reactive compounds identified from HTS exercises, which are then removed from follow-up processes, thus obviating the generation of data from biochemical activity assays.
Collapse
Affiliation(s)
- Cong Wei
- 1Pharmaceutical Candidate Optimization, Molecular Sciences & Candidate Optimization, Research and Development, Bristol-Myers Squibb, Wallingford, CT, USA
| | | | | | | | | | | |
Collapse
|
9
|
Abstract
High-resolution MS (HRMS) in conjunction with LC (LC–HRMS) has become available to many laboratories in the pharmaceutical industry. Due to its enhanced, though sometime perceived, specificity using the high-resolution power and its capability of simultaneous quantitation and structural elucidation using the post-acquisition data mining feature, utilization of LC–HRMS for bioanalysis could lead to potential rapid and reliable method development as well as sample analysis, thus generating both cost and resource savings. Here, we would like to share our perspectives about several current and future applications of LC–HRMS in bioanalysis. We will also discuss the factors influencing the quality of method establishment and potential pitfalls that need to be considered for the utilization of LC–HRMS in the field of regulated bioanalysis. We believe when utilized appropriately, LC–HRMS will play a significant role in the future landscape of quantitative bioanalysis.
Collapse
|
10
|
Exploring the utility of high-resolution MS with post-acquisition data mining for simultaneous exogenous and endogenous metabolite profiling. Bioanalysis 2013; 5:1211-28. [DOI: 10.4155/bio.13.102] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Background: The utility of high-resolution MS (HRMS) with post-acquisition data mining in DMPK goes much further than the now established approach to simultaneously acquire quantitative and qualitative information for lead compounds at the discovery stage. Indeed, HRMS has promise for addressing multiple complex drug-development applications in a single experiment. In the present study, one HRMS dataset acquired for in vitro incubations of the model compound dasatinib was mined post-acquisition to address four different issues: stability, metabolite profiling, glutathione conjugate analysis, and endogenous lipid profiling. Results & Conclusion: The derived results demonstrated that HRMS has potential for generating high information content datasets that can be stored and mined as needed to answer numerous complex development-stage questions without the need for additional sample generation or analysis.
Collapse
|
11
|
Utility of high-resolution accurate MS to eliminate interferences in the bioanalysis of ribavirin and its phosphate metabolites. Bioanalysis 2013; 4:1895-905. [PMID: 22943620 DOI: 10.4155/bio.12.151] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
BACKGROUND The polar nucleoside drug ribavirin (RBV) combined with IFN-α is a front-line treatment for chronic hepatitis C virus infection. RBV acts as a prodrug and exerts its broad antiviral activity primarily through its active phosphorylated metabolite ribavirin 5´-triphosphate (RTP), and also possibly through ribavirin 5´-monophosphate (RMP). To study RBV transport, diffusion, metabolic clearance and its impact on drug-metabolizing enzymes, a LC-MS method is needed to simultaneously quantify RBV and its phosphorylated metabolites (RTP, ribavirin 5´-diphosphate and RMP). In a recombinant human UGT1A1 assay, the assay buffer components uridine and its phosphorylated derivatives are isobaric with RBV and its phosphorylated metabolites, leading to significant interference when analyzed by LC-MS with the nominal mass resolution mode. RESULTS Presented here is a LC-MS method employing LC coupled with full-scan high-resolution accurate MS analysis for the simultaneous quantitative determination of RBV, RMP, ribavirin 5´-diphosphate and RTP by differentiating RBV and its phosphorylated metabolites from uridine and its phosphorylated derivatives by accurate mass, thus avoiding interference. CONCLUSION The developed LC-high-resolution accurate MS method allows for quantitation of RBV and its phosphorylated metabolites, eliminating the interferences from uridine and its phosphorylated derivatives in recombinant human UGT1A1 assays.
Collapse
|
12
|
The future key role of LC–high-resolution-MS analyses in clinical laboratories: a focus on quantification. Bioanalysis 2012; 4:2939-58. [DOI: 10.4155/bio.12.243] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
For the last decade, high-resolution (HR)-MS has been associated with qualitative analyses while triple quadrupole MS has been associated with routine quantitative analyses. However, a shift of this paradigm is taking place: quantitative and qualitative analyses will be increasingly performed by HR-MS, and it will become the common ‘language’ for most mass spectrometrists. Most analyses will be performed by full-scan acquisitions recording ‘all’ ions entering the HR-MS with subsequent construction of narrow-width extracted-ion chromatograms. Ions will be available for absolute quantification, profiling and data mining. In parallel to quantification, metabotyping will be the next step in clinical LC–MS analyses because it should help in personalized medicine. This article is aimed to help analytical chemists who perform targeted quantitative acquisitions with triple quadrupole MS make the transition to quantitative and qualitative analyses using HR-MS. Guidelines for the acceptance criteria of mass accuracy and for the determination of mass extraction windows in quantitative analyses are proposed.
Collapse
|
13
|
Abstract
New analytical platforms have been developed in response to the need for attaining increased peak capacity for multicomponent complex analysis with higher sensitivity and characterization of the analytes, and high-throughput capabilities. This review outlines the fundamental principles of target and comprehensive 2D LC method development and encompasses applications of LC–LC and LC × LC coupled to MS in bioanalysis using a variety of online analytical procedures. It also provides a rationale for the usage of the most employed mass analyzers and ionization sources on these platforms.
Collapse
|
14
|
Quantitative/qualitative analysis using LC–HRMS: the fundamental step forward for clinical laboratories and clinical practice. Bioanalysis 2012; 4:1709-11. [DOI: 10.4155/bio.12.159] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|